Virtual health provider Transcarent announced Monday that it will acquire digital health company 98point6 in a $100 million deal, which will allow Transcarent to gain access to 98point6’s AI-powered virtual care platform.
The $100 million…
A new study from Boston University found that experiences of racism can lead to a 26% greater risk of coronary heart disease in Black women. The study, which…
Continue Reading
Chroma Medicine, a biotech company developing therapies that turn genes on or off as a way of treating genetic disorders, has raised $135 million as it works to generate data that could show the…
Continue Reading
By Mark Melchionna March 03, 2023 – Published in the Journal of the American Heart Association, a new study found that among US military veterans hospitalized for cardiac issues, those who took…
Continue Reading
Nearly one in five people who are incarcerated battle opioid use disorder (OUD), and opioid-related overdose is the leading cause of death for those released from the criminal justice system. A new collaboration aims…
Continue Reading
Physicians spend more than 16 minutes on average per patient visit using electronic health records (EHRs), research shows. At a time when clinician burnout is at an all-time high, one company is trying to…
Continue Reading
Ambience AutoScribe technology, custom-built for medicine, works in real time without human scribes
Providers using the technology reduce their documentation time by 76% on average
Company backed by top-tier investors including Andreessen Horowitz, Human Capital, Kleiner…
Continue Reading
Elation Health — a San Francisco-based company that sells its electronic health record (EHR) and other technology solutions to primary care providers — on Thursday announced its acquisition of medical billing firm Lightning MD.
The deal will help Elation become an all-in-one technology platform for primary care offices, CEO Kyna Fong said in a recent interview. Fong founded Elation with her brother in 2010. The siblings grew up in Canada, where their father was a primary care physician — and a passionate one. He was so passionate that he ended up moving his family to the U.S. because he couldn’t “practice the…
Vir Biotechnology’s Covid-19 research may yield more drugs and perhaps a vaccine, but no longer with the financial support of GSK. The collaboration agreement the two companies struck up in the early days of the pandemic has been amended, leaving Vir to either find another partner or continue its coronavirus research on its own.
The alliance did successfully develop the Covid-19 drug sotrovimab. GSK and Vir will continue to share responsibilities for that drug, which is available under the brand name Xevudy in more than 40 countries. The U.S. is no longer one of them. Last April, the FDA withdrew emergency authorization…
Subscribe for your weekly fix of health tech stories, wherever you get your news: Apple, Spotify or Twitter.Dr. Anne-Maree Cantwell, Partner at Empactful CapitalIn this episode, I sat down with Anne-Maree Cantwell, Venture Partner at…
Continue Reading
